Vagus nerve stimulation in children with mitochondrial electron transport chain deficiencies

Todd M Arthur1, Russell P Saneto, Marcio Sotero de Menezes

  • 1Division of Pediatric Neurology, Children's Hospital and Regional Medical Center/University of Washington, B-5552, 4800 Sand Point Way NE, Seattle, WA 98105, USA.

Mitochondrion
|May 22, 2007
PubMed

Insights

Vagus nerve stimulation (VNS) showed limited effectiveness in reducing seizure frequency in five young children with intractable epilepsy and mitochondrial disease. This epilepsy treatment may not be suitable for myoclonic seizures in electron transport chain disorders.

Area of Science:

  • Pediatric Neurology
  • Mitochondrial Diseases
  • Epilepsy Treatment

Background:

  • Intractable seizures in children often require advanced treatment options.
  • Mitochondrial diseases, particularly electron transport chain deficiencies, can cause severe neurological symptoms like epilepsy.
  • Vagus nerve stimulation (VNS) is an established therapy for refractory epilepsy.

Purpose of the Study:

  • To evaluate the efficacy of vagus nerve stimulation (VNS) in pediatric patients under 12 years old with intractable seizures and mitochondrial disease.
  • To analyze seizure frequency reduction and other clinical outcomes following VNS implantation in this specific patient cohort.

Main Methods:

  • Retrospective investigation of outcome data from five children diagnosed with mitochondrial disease and intractable seizures.
  • Data collection included seizure types/frequency, EEG, neuroimaging, and medication history before and after VNS implantation.

Main Results:

  • None of the five pediatric patients experienced a significant reduction in seizure frequency with VNS.
  • Four children presented with predominantly myoclonic seizures; one had focal seizures with secondary generalization and myoclonic seizures.

Conclusions:

  • Vagus nerve stimulation (VNS) appears to be ineffective for controlling myoclonic seizures in children with electron transport chain disorders.
  • Further research is needed to explore alternative or adjunctive therapies for epilepsy in pediatric mitochondrial diseases.

Related Concept Videos

Motor Unit Stimulation01:20

Motor Unit Stimulation

When the neuron of a motor unit fires an action potential, it triggers a series of events, leading to a twitch contraction in the muscle fibers. The process of excitation-contraction coupling is crucial in relaying the action potential to the muscle fibers.
The latent period of contraction marks the onset of excitation-contraction coupling, when the action potential propagates across the sarcolemma, preparing the muscle fibers for contraction. As the fibers enter the contraction phase, the...
Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...